Dr. Vinod Parameswaran, MD
- Medicare services, 2023
- 782
- Part D claims, 2024
- 124
- Publications
- 3
- Clinical trials
- 7
- Hospital affiliations
- 1
- Practice address
- 714 Lincoln St NE, Le Mars, IA 51031
- Practice phone
- Call (712) 546-7871
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Parameswaran's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Vinod Parameswaran is a hematologist and oncologist in Le Mars, Iowa
Dr. Parameswaran practices at Floyd Valley Healthcare in Le Mars, Iowa, part of Le Mars Iowa.
Dr. Parameswaran's NPI, 1013983352, was assigned on February 27, 2006. Dr. Parameswaran holds South Dakota license 5149.
- NPI
- 1013983352NPI Registry (opens in a new tab)
- NPI enumeration date
- February 27, 2006
- NPI status
- Active
- Practice phone
- (712) 546-7871
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 63
- Medical school graduation
- 1989
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Affiliation Data
Dr. Vinod Parameswaran practices at Floyd Valley Healthcare in Le Mars, Iowa
Dr. Parameswaran's primary practice is Floyd Valley Healthcare, at 714 Lincoln St NE, Le Mars, IA 51031 in Plymouth County. The practice phone is (712) 546-7871.
- Floyd Valley Healthcare714 Lincoln St NE, Le Mars, IA 51031 · Plymouth CountyPhone(712) 546-7871
Source: Dmand AI Affiliation Data
Dr. Vinod Parameswaran is affiliated with 2 sites of care and 1 medical group
Dr. Parameswaran's primary practice is Floyd Valley Healthcare in Le Mars, Iowa, part of Le Mars Iowa. The medical group on file is Avera McKennan Hospital & University Health Center. Dmand AI also links Dr. Parameswaran to 1 more group practice or clinic, named with a free account.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Vinod Parameswaran's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Parameswaran practices, 2 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Floyd Valley Healthcare | Available with a free account |
| +1 more affiliated site | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across Le Mars Iowa and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Vinod Parameswaran is one of 77 hematologists and oncologists in Iowa
Hematology and oncology is Dr. Parameswaran's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Parameswaran is licensed in South Dakota.
Specialties and state licenses
- Hematology and oncology, South DakotaPrimary
Hematologists and oncologists near Dr. Parameswaran
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Vinod Parameswaran billed Medicare for 782 services in 2023
CMS data shows 782 Medicare services from Dr. Parameswaran across 8 procedure codes in 2023. Medicare paid $44,874 for them.
Dr. Parameswaran's Medicare services by type, 2022 to 2023
- 2022
- 2023
- Office and hospital visits
- 2022: 1,5762023: 70255%
- Surgery
- 2022: 1372023: 4269%
- Tests and treatments
- 2022: 1202023: 3868%
Where Dr. Parameswaran's Medicare services took place, 2023
- In an office27936%
- In a facility50364%
Dr. Parameswaran compared with the Iowa median for hematologists and oncologists, 2023
- Dr. Parameswaran
- Iowa median
- Medicare services
- 782vs 759Close to median
- Part D claims
- 82vs 25468% below
Medians across 78 hematologists and oncologists in Iowa with Dmand AI profiles that report each measure.
Dr. Parameswaran's most billed Medicare procedure codes, 2023
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Parameswaran?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Parameswaran and other hematologists and oncologists in Iowa.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Vinod Parameswaran's patients have a median age of 75
Across all payers, Dmand AI patient panel data puts Dr. Parameswaran's median patient age at 75, with 43% women.
Dr. Parameswaran's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 75
Patient panel by sex, all payers
- Women43%
- Men57%
Source: Dmand AI Patient Panel Data
Dr. Vinod Parameswaran wrote 124 Medicare Part D claims in 2024
In 2024, Dr. Parameswaran wrote 124 Medicare Part D claims for 22 patients. 73% of them were for generic drugs. CMS names the drug for 82 of them, across 4 drugs with 11 or more claims each, at $242,196 in total drug cost. In 2023, CMS named 240 claims across 8 drugs.
Dr. Parameswaran's Part D claims by kind of drug, 2024
- Generic90 claims73%
- Brand-name34 claims27%
Dr. Parameswaran's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Parameswaran's Part D claims, 2024
- Antibiotics10%12 of 124 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 2402024: 8266%
Drugs named by CMS: 4 in 2024, 8 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Vinod Parameswaran has 3 publications on record
Dmand AI links 3 papers to Dr. Parameswaran, published from 2018 to 2024. Dr. Parameswaran's most frequent co-authors are Edmund K. Waller, MD, Luke Paul Akard, MD and Paolo Anderlini, MD.
Dr. Parameswaran's papers by year, 2018 to 2024
Dr. Parameswaran's most frequent co-authors
- Edmund K. Waller, MD2 shared papers
- Luke Paul Akard, MD1 shared paper
- Paolo Anderlini, MD1 shared paper
Recent publications by Dr. Parameswaran
See who Dr. Parameswaran researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Parameswaran works with, so you can find a warm path to the right hematologists and oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Vinod Parameswaran has worked on 7 clinical trials
Dmand AI links Dr. Parameswaran to 7 clinical trials, 5 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Cytopenia. ECOG-ACRIN Cancer Research Group sponsors the most, 3.
Conditions in Dr. Parameswaran's trials
- Multiple Myeloma
- Blood Protein Disorders
- Cytopenia
- Graft vs Host Disease
- Smoldering Multiple Myeloma
Investigators on the most trials with Dr. Parameswaran
- Abraham Sebastian Kanate, MD3 shared trials
- Bruce B. Bank, MD2 shared trials
- Elizabeth A. Brem, MD2 shared trials
Recent clinical trials with Dr. Parameswaran
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant (opens in a new tab)
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial (opens in a new tab)
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma (opens in a new tab)
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (opens in a new tab)
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Vinod Parameswaran received $139 in industry payments from 2018 to 2023
CMS Open Payments shows 6 general payments to Dr. Parameswaran from 4 drug and device companies from 2018 to 2023. Education make up the largest share, 84% of the total. Bristol-Myers Squibb Company paid the most, $96.
General payments to Dr. Parameswaran by program year, 2018 to 2023
General payments to Dr. Parameswaran by kind, 2018 to 2023
- Education$11784%
- Food and beverage$2216%
Companies that paid Dr. Parameswaran the most, 2018 to 2023
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Vinod Parameswaran's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Vinod Parameswaran
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Vinod Parameswaran's NPI number?
Dr. Vinod Parameswaran's NPI number is 1013983352. It was assigned on February 27, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. Vinod Parameswaran?
Dr. Vinod Parameswaran is a hematologist and oncologist in Le Mars, Iowa. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Vinod Parameswaran practice?
Dr. Parameswaran practices at 714 Lincoln St NE, Le Mars, IA 51031. Dr. Parameswaran's primary practice is Floyd Valley Healthcare in Le Mars, Iowa, part of Le Mars Iowa. Dmand AI also links Dr. Parameswaran to 1 group practice or clinic.
What is Dr. Vinod Parameswaran's office phone number?
The practice phone on file for Dr. Parameswaran is (712) 546-7871.
What is Dr. Vinod Parameswaran's medical license number?
Dr. Parameswaran holds South Dakota license 5149.
Which hospitals is Dr. Vinod Parameswaran affiliated with?
Dr. Parameswaran practices at Floyd Valley Healthcare in Le Mars, Iowa.
What medical group is Dr. Vinod Parameswaran part of?
Dr. Parameswaran is linked to Avera McKennan Hospital & University Health Center.
Does Dr. Vinod Parameswaran accept Medicare?
Yes. CMS data shows Dr. Parameswaran billed Medicare for 782 services in 2023.
What services does Dr. Vinod Parameswaran bill to Medicare?
In 2023, Dr. Parameswaran's most billed Medicare services were office visit, established patient (99214), office visit, established patient (99213) and hospital inpatient care (99233).
What drugs does Dr. Vinod Parameswaran prescribe most?
In 2024 Medicare Part D data, Dr. Parameswaran's most prescribed drugs by claims were Acyclovir, Promacta and Jakafi.
Show 4 more questionsShow fewer questions
Has Dr. Vinod Parameswaran received payments from drug or device companies?
CMS Open Payments shows $139 in general payments to Dr. Parameswaran from 4 companies from 2018 to 2023. The largest total came from Bristol-Myers Squibb Company.
How long has Dr. Vinod Parameswaran been practicing?
Dr. Parameswaran graduated from medical school in 1989, 37 years ago.
Does Dr. Vinod Parameswaran do research?
Dmand AI links 3 publications to Dr. Parameswaran, published from 2018 to 2024. Dr. Parameswaran has worked on 7 clinical trials.
Who does Dr. Vinod Parameswaran publish with?
Dr. Parameswaran's most frequent co-authors are Edmund K. Waller, MD (2 shared papers), Luke Paul Akard, MD (1 shared paper) and Paolo Anderlini, MD (1 shared paper).
Selling to hematology and oncology practices?
See hematologists and oncologists in Iowa by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card